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Abstract
Background
In Vietnam, the importance of vivax malaria relative to falciparum during the past decade
has steadily increased to 50%. This, together with the spread of multidrug-resistant Plasmo-
dium falciparum, is a major challenge for malaria elimination. A 2-year prospective cohort
study to assess P. vivax morbidity after radical cure treatment and related risk factors was
conducted in Central Vietnam.
Methods and findings
The study was implemented between April 2009 and December 2011 in four neighboring vil-
lages in a remote forested area of Quang Nam province. P. vivax-infected patients were
treated radically with chloroquine (CQ; 25 mg/kg over 3 days) and primaquine (PQ; 0.5 mg/
kg/day for 10 days) and visited monthly (malaria symptoms and blood sampling) for up to 2
years. Time to first vivax recurrence was estimated by Kaplan–Meier survival analysis,
and risk factors for first and recurrent infections were identified by Cox regression models.
Among the 260 P. vivax patients (61% males [159/260]; age range 3–60) recruited, 240
completed the 10-day treatment, 223 entered the second month of follow-up, and 219 were
followed for at least 12 months. Most individuals (76.78%, 171/223) had recurrent vivax
infections identified by molecular methods (polymerase chain reaction [PCR]); in about
half of them (55.61%, 124/223), infection was detected by microscopy, and 84 individuals
(37.67%) had symptomatic recurrences. Median time to first recurrence by PCR was 118
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days (IQR 59–208). The estimated probability of remaining free of recurrence by month 24
was 20.40% (95% CI [14.42; 27.13]) by PCR, 42.52% (95% CI [35.41; 49.44]) by micros-
copy, and 60.69% (95% CI [53.51; 67.11]) for symptomatic recurrences. The main risk fac-
tor for recurrence (first or recurrent) was prior P. falciparum infection. The main limitations of
this study are the age of the results and the absence of a comparator arm, which does not
allow estimating the proportion of vivax relapses among recurrent infections.
Conclusion
A substantial number of P. vivax recurrences, mainly submicroscopic (SM) and asymptom-
atic, were observed after high-dose PQ treatment (5.0 mg/kg). Prior P. falciparum infection
was an important risk factor for all types of vivax recurrences. Malaria elimination efforts
need to address this largely undetected P. vivax transmission by simultaneously tackling the
reservoir of P. falciparum and P. vivax infections.
Author summary
Why was this study done?
• WHO currently recommends a 14-day primaquine (PQ) regimen at 0.5 mg/kg/day
together with chloroquine (CQ; 25 mg/kg over 3 days) for the radical cure of P. vivax
infections in Southeast Asia.
• Between 2007 and 2009, Vietnam introduced a high-dose PQ regimen shortened to 10
days in an attempt to improve patient compliance.
• A 2-year one-arm cohort study was conducted between May 2009 and December 2011
in four remote villages of Central Vietnam to determine the incidence and risk factors
for vivax recurrence after the new radical cure regimen.
What did the researchers do and find?
• 260 P. vivax-infected patients were enrolled between May 2009 and December 2010,
received directly observed 10-day treatment, and were followed up monthly for up to 24
months.
• During scheduled and unscheduled visits, participants were examined, and blood sam-
ples were systematically taken for light microscopy (LM) and polymerase chain reaction
(PCR) analysis. All LM-detected vivax infections (patent) were treated with CQ alone,
while PQ was given at the end of individual follow-up.
• Time-to-event analysis showed that by month 24, only 20% of patients remained free of
vivax recurrences detected by PCR, while this was 40% for patent (by LM) recurrences.
The majority of recurrences were submicroscopic and asymptomatic because only 38%
of patients had symptomatic recurrences.
• The main risk factors for P. vivax recurrences were prior P. falciparum infections, espe-
cially submicroscopic, and prior treatment of vivax infections with CQ.
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What do these findings mean?
• Despite the age (10 years) of the data collected, the results of this cohort study remain
relevant to the current malaria situation in Vietnam, where the elimination of vivax
malaria and of multidrug-resistant P. falciparum are major challenges.
• A substantial proportion of the vivax malaria reservoir is not detected by current sur-
veillance strategies in Vietnam, i.e., passive and re-active case detection based on LM/
rapid diagnostic tests (RDTs).
• Prior P. falciparum infections (including submicroscopic) and vivax infections treated
with CQ alone were significant risk factors for vivax recurrences.
• To further improve vivax elimination efforts in Vietnam, new treatment strategies (i.e.,
single-dose radical treatment) and more sensitive diagnostic tools (i.e., field PCR/ultra-
sensitive RDTs) simultaneously tackling falciparum and vivax malaria infections are
needed.
Introduction
Radical cure of P. vivax malaria, the most prevalent species outside sub-Saharan Africa [1],
remains a challenge because preventing subsequent relapses and onward transmission requires
treatment of both circulating blood (schizonticidal drugs) and the dormant liver (hypnozoitici-
dal drug) stages [2]. Chloroquine (CQ) and primaquine (PQ) have been combined for this
purpose since the late 1950s, and PQ—an 8-aminoquinoline licensed in 1952—remained the
only antirelapse therapy available until July 2018 [3]. Its use implies several challenges, includ-
ing the risk of acute hemolysis in Glucose-6-Phosphate-dehydrogrenase–deficient (G6PDd)
patients and poor adherence to the 14-day treatment schedule [2]. Moreover, the rapid spread
of P. vivax CQ resistance will require alternative blood schizonticides and thus new combina-
tions for radical cure to be tested [4]. Over the past 60 years, various PQ regimens have been
used [5], and currently the World Health Organization (WHO) guidelines recommend PQ at
0.25 mg/kg/day for 14 days, together with CQ or an artemisinin-based combination therapy
(ACT) [6]. In Southeast Asia and Oceania, where the vivax Chesson strain is prevalent, a
higher PQ daily dose (0.5 mg/kg/day; 7.0 mg/kg total dose) is recommended.
In Vietnam, the importance of P. vivax malaria has recently increased following the suc-
cessful control efforts against P. falciparum [7] and the recent country’s commitment to elimi-
nate malaria by 2030 [8]. Currently, malaria transmission remains confined in forested areas
of Central Vietnam, with the highest incidence reported along the international borders with
Laos and Cambodia [9]. Between 2011 and 2015, the annual incidence of confirmed malaria
cases dropped by 44% (i.e., from 16,612 to 9,331) and malaria deaths by 79% (3 deaths
recorded in 2015). Concomitantly, the annual incidence of confirmed P. falciparum cases
decreased by 57% (from 10,101 to 4,327 cases) while P. vivax cases decreased only by 15%
(from 5,602 to 4,756 cases). Consequently, the frequency of P. vivax relative to P. falciparum
increased from 34% to 51%, a significant change because P. vivax consistently accounted for
20%–30% of all malaria cases since 1991 [10].
In the framework of the current National Malaria Control and Elimination Program
(NMCEP) launched in 2011, surveillance strategies include both passive case detection (PCD)
using light microscopy (LM) or rapid diagnostic tests (RDTs) (at the health centers, hospitals,
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and private clinics) and re-active case detection (Re-ACD) following the detection of any
malaria case (“index case”) by PCD at community level [11]. Re-ACD consists of screening all
residents within 20–30 houses around the index case for malaria (using RDTs/LM) and treat-
ing all positive individuals. Re-ACD is done by a mobile team (including health staff and Ham-
let Health Workers [HHWs]) as part of the “2-4-7 surveillance and response strategy” adapted
from China [12]. All antimalarial treatments are provided free of charge by the NMCEP, and
the current guidelines for the radical treatment of P. vivax recommend the use of PQ at 0.25
mg/kg/day for 14 days together with CQ for 3 days [13].
However, over the past 20 years, treatment guidelines for vivax malaria in Vietnam have
changed several times, illustrating the difficult balance between maximizing the effectiveness
of and compliance to PQ while minimizing the risk of acute hemolysis in G6PDd patients.
Therefore, after the 5-day PQ regimen at 0.5 mg/kg/day introduced in 1997, guidelines were
changed to 0.25 mg/kg/day for 10 days in 2003 and to 0.50 mg/kg/day for 10 days between
2007 and 2009, the latter of which was used in the present study [14]. However, in 2009, this
high-dose regimen was again changed to PQ at 0.25 mg/kg/day for 14 days [15] following
increased fear of hemolysis in the absence of readily available G6PD testing. In remote areas of
Central Vietnam, where treatment monitoring is challenging, adherence to PQ treatment is
reportedly low because of both fear by the health staff of acute hemolysis in G6PDd patients
and poor patient compliance to the 14-day course [16]. These challenges related to PQ treat-
ment are commonly reported in all vivax-endemic areas [17,18].
We report here the results of a cohort study in which P. vivax patients were treated radically
with the previously recommended high-dose PQ regimen (0.50 mg/kg/day for 10 days) and
followed up monthly for up to 2 years, with the aim of evaluating the post-treatment transmis-
sion dynamics of recurrent vivax infections.
Materials and methods
Data were collected following a prospective study protocol that did not include a detailed pro-
spective statistical analysis plan (S1 Text).
Study design
This is a 2-year prospective cohort study carried out in Central Vietnam in which P. vivax-
infected patients were followed up monthly after radical treatment. At each visit, a clinical
examination and blood sampling for malaria parasite identification by LM and polymerase
chain reaction (PCR) were performed. During the follow-up, vivax recurrent infections identi-
fied by LM and/or symptomatic infections were treated with CQ alone. This aimed at better
determining the vivax parasite reservoir in real-life conditions because PQ was not usually
administered to these patients at the time this project was implemented.
Study site and population
The study was implemented between April 2009 and December 2011 in four neighboring vil-
lages (Villages 1–3 in the Tra Leng commune and Village 4 in the Tra Don commune) in the
mountainous and forested district of Nam Tra My in Quang Nam province. Villages were
organized in several scattered clusters of about 4 to 45 households each (total population of
1,810 individuals according to the March 2009 census). A detailed description of the sociode-
mographic characteristics and malariometric indices of this study area has been published else-
where [19]. Briefly, the study population belonged to the M’nong (Villages 1–3) and Cadong
(Village 4) ethnic groups, living mainly off slash-and-burn agriculture and cinnamon planta-
tions in forest fields. Malaria transmission is perennial with two peaks, May–June and
P. vivax morbidity after radical cure: A cohort study in Central Vietnam
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002784 May 17, 2019 4 / 23
October–November, with two main vector species: Anopheles dirus sensu stricto and A. mini-
mus sensu stricto [20,21]. In April 2009, at baseline, malaria prevalence in the four study vil-
lages was 7.8% by LM and 23.6% by PCR, with 60% P. falciparum and the remaining P. vivax
infections [19]. The G6PD genetic polymorphism (Vianchiang mutation) was estimated at less
than 1.5% in both males and females, with no difference between ethnic groups.
Data collection
P. vivax-infected patients were first identified during the baseline survey (April–May 2009)
[19] and then by PCD at the Tra Leng Community Health Center (CHC) (May 2009–Dec
2010) until the target sample size was reached (see below). Inclusion criteria were age�3 years
(following contemporary guidelines [14]; changed to�6 months in the current guidelines
[15]) and�60 years old, axillary temperature�37.5 ˚C and/or history of fever in the previous
48 hours, microscopically confirmed P. vivax monoinfection (asexual stage), permanent resi-
dency in the study area, and ability and willingness to participate in the study confirmed by a
written informed consent (parents/guardians for patients <18 years). Patients were excluded if
they had any danger signs or severe malaria, any concurrent infection or underlying chronic
condition (e.g., tuberculosis [TB], HIV, epilepsy, etc.) requiring specific treatment, severe mal-
nutrition, known allergy or intolerance to study drugs, prior PQ treatment within the past
month, or if they were pregnant (as confirmed by rapid test) or breastfeeding. Patients were
treated daily with CQ (25 mg/kg over 3 days) and PQ (0.5 mg/kg/day for 10 days) according to
the contemporary national guidelines [15]. During the first 10 days of follow-up, patients were
examined daily, and treatment was directly observed. Patients were then asked to attend the
CHC at day 14, 21, and 28 or if ill between scheduled visits. Any patent vivax recurrence was
considered as treatment failure; patients received rescue treatment (dihydroartemisinin-piper-
aquine [DHA-PQ]) and PQ (10 days), and follow-up was stopped. From day 28 onwards,
monthly home visits were done either until completing 2-year follow-up or the end of study in
December 2011. Between scheduled visits, patients were advised to consult their HHW or the
study team at the CHC if unwell. At each visit (scheduled or unscheduled), they were systemat-
ically interviewed, body temperature was collected, and a finger prick blood sample was taken
for LM (thick and thin film) and later molecular analysis (filter paper blood sample [FPBS]).
Any LM-confirmed P. vivax infection identified during the monthly follow-up was treated
with a 3-day course of CQ; PQ was given to all patients at the end of the follow-up. In addition,
LM-confirmed P. falciparum infections (either mono- or mixed infections) were treated with a
3-day course DHA-PQ as per national guidelines. All patients were closely followed up by the
study team for the detection of adverse events, which were managed as per study protocol.
Definitions
The main study outcomes were the incidence and risk factors for vivax recurrence as measured
by time-to-event analysis. A recurrence was defined as a vivax infection detected after the ini-
tial post-treatment parasite clearance. Because the parasite reservoir in low-transmission set-
tings is mostly represented by submicroscopic (SM) and asymptomatic infections [19,22],
vivax recurrences were systematically detected by both PCR (Seminested Multiplex [SnM]
PCR detecting densities below 1 parasite/μl [23,24]) and LM (detection limit of 10–50 para-
sites/μl for experienced technicians). Therefore, three outcome variables were defined as
follows: i) all recurrences identified by PCR (= “all PCR-detected recurrences”); ii) all recur-
rences identified by PCR and LM (= “patent recurrences”); and iii) all patent recurrences with
malaria symptoms (i.e., body temperature�37.5 ˚C and/or other symptoms; = “symptomatic
recurrences”).
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The following covariates were considered for the risk factor analysis: village, ethnic groups
(M’nong, Ca Dong), gender, age, occupation (farmers, other), bed net in house (none, at least
one), economic level (low, medium, high), year of recruitment (2009, 2010), season of recruit-
ment (dry, rainy), parasite density at day 0 (parasite/μl), and “prior P. falciparum infection
within 2 months before P. vivax recurrence” (i.e., all PCR-detected P. falciparum infections).
In addition, we also explored whether being treated with an antimalarial (ACT or CQ) during
the previous visit was associated with a higher risk of P. vivax recurrence. Among risk factors,
the economic level was computed using three different variables for livestock ownership, i.e.,
number of i) buffaloes, ii) cows, and iii) pigs, and by using principal component analysis as
described previously [19].
Laboratory procedures
Parasite species and density were determined by LM. Thin films were fixed with methanol for
15–30 seconds; both thin and thick smears were stained with 3% Giemsa solution for 45 min-
utes. P. vivax and P. falciparum asexual stages were counted against 200 white blood cells
(WBCs), assuming a mean WBC count of 8,000/μl. Quality control was done at the National
Institute of Malariology, Parasitology, and Entomology (NIMPE), Hanoi, Vietnam by a senior
technician blinded to patients’ details. All positive blood slides and 10% of randomly chosen
negative slides were double-checked; in case of discrepancy, slides were read by a third senior
technician.
FPBSs were first stored at 4 ˚C until transferred to NIMPE where they were stored at −20
˚C until processing. DNA extraction was done using the QIAamp DNA Micro Kit (Qiagen,
Hilden Germany); a species-specific SnM-PCR to detect the four human Plasmodium species
was performed [25]. Quality control was done at the Institute of Tropical Medicine, Antwerp
(ITMA) by a senior technician who blindly reread 10% of randomly chosen blood samples.
Sample size
The sample size was calculated on the basis of P. vivax CQ failure rates in different sentinel
sites in Central Vietnam, ranging from 0% to 5.7% [26]. Assuming 5% treatment failure at day
28 post-treatment and 10% loss to follow-up, 205 patients would provide 3% precision at a 5%
significance level (“CSample” command/Epi Info6). Beyond 28 days post-treatment, it was
assumed that 20% of the remaining patients would be lost to follow-up. Therefore, an addi-
tional security margin was added to start with a cohort of 250 patients, resulting in 205 patients
with complete follow-up data points (i.e., D0 + 24 monthly records).
Data analysis
Data were double entered and checked in Epidata version 3.1 (The EpiData Association,
Odense M, Denmark), and analyzed using STATA version 11 (Stata Corp, College Station,
TX, USA). The study design was taken into account at all steps of the analysis by setting the
data with household as primary sampling unit and village as strata (alpha = 0.05) using the sur-
vey (“svy”) command in STATA.
All patients entered the follow-up at D0 until censoring, which occurred when patients
were lost follow-up, had a treatment failure during the first 28 days, or at the end of the
monthly follow-up. Any patent recurrence after day 28 was systematically treated with CQ (3
days) and considered as an independent event from the next one. However, the SM recur-
rences that could be detected for several consecutive months in the same individual (but were
not treated because they were identified months later) were considered as “positive PCR per-
son-month.”
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Summary statistics (accounting for study design) were used to describe the baseline charac-
teristics at inclusion and at subsequent visits. Incidence rate of vivax recurrences were calcu-
lated by dividing the number of recurrent episodes by the person-years at risk and expressed
as the number of recurrences per person-years at risk. The Wilcoxon sign rank test was used
to compare the median time intervals between consecutive recurrences identified by PCR.
Time to first P. vivax recurrence post-treatment was analyzed by Kaplan–Meier survival
analysis, which estimated the probability for patients to remain free of any vivax recurrence
(PCR-detected, patent, or symptomatic) as well as of any P. falciparum infection (detected by
PCR). To minimize the risk of vivax infections acquired outside the study area, individuals
absent from the study area for two or more consecutive visits were censored at their last visit.
In case of a single monthly visit missed, this was not considered as a missing month if the indi-
vidual had remained within the study site, while if s/he had left the study area, it was consid-
ered as a person-time at risk censored at the time s/he was absent.
The time at risk to first recurrence was counted as days from D0 to first vivax recurrence,
while for any subsequent recurrence, the time at risk was counted as days since the previous
recurrence. Patients treated with either CQ (patent P. vivax recurrence) or DHA-PQ (patent
P. falciparum infection) were censored for 14 days post-treatment.
The risk factor analysis was conducted both for the first and recurrent vivax recurrences. A
uni- and multivariable-adjusted Cox Proportional Hazard (PH) regression model (Hazard
Ratio [HR]) was used to identify significant risk factors for the first PCR-detected P. vivax
recurrence (first recurrence per subject). A Cox Conditional Gap Time (CGT) model was used
to assess the risk for recurrent infections per subject over time [27,28]. In this model, each
recurrence was analyzed separately and stratified by recurrence order, the underlying assump-
tion being that a subject was not at risk of a second recurrence until the first recurrence had
occurred. Thus, the conditional risk set at time for recurrence k (tk) was made up for all sub-
jects under observation at time they had had recurrence k − 1. This method considers the total
number of recurrences analyzed and the time at risk between each recurrence. The extra corre-
lation due to repeated observations within patients was accounted for (using the vce (cluster
ID) option within the “stcox” command in the CGT model). Interactions were systematically
checked up to order two. The PH assumption was tested for each Cox model.
Ethical clearance
Ethical clearance was obtained from the ethical committees of both the NIMPE, Hanoi and the
University of Antwerp. The fundamental principles of ethics in research on human partici-
pants were upheld throughout the project. The study objectives and methods were first
explained to the community leaders for their approval. Each study participant provided a writ-
ten informed consent following explanation of the study objectives and follow-up procedures
as well as their right to withdraw without prejudice for themselves or their families. For minors
(<18 years old), parents/guardians signed the individual informed consent, while individuals
aged 12–18 were asked to provide individual assent.
Results
Cohort characteristics
A total of 260 P. vivax-infected patients were identified and enrolled (21 during initial survey;
239 during PCD). Of these, 20 (7.69%) patients withdrew consent and did not complete the
10-day radical cure (Fig 1). By day 28 (first monthly visit), 9 additional patients had withdrawn
consent, and 8 had treatment failure, were treated with DHA-PQ (3 days) and PQ (10 days),
and were excluded as per protocol. Therefore, after day 28, the cohort comprised 223 patients,
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of whom 4 withdrew consent (moved out of study area), 219 completed at least 12 months,
and 107 completed 24 months of follow-up. Overall, 33 patients (33/260 = 12.7%) withdrew
consent, mainly (20/33 = 60.6%) during the 10-day PQ treatment. Total individual follow-up
times ranged from 9 to 719 days, with a median of 628 days (IQR 508–718), and none of the
participants were censored because of prolonged absence outside the study area.
Fig 1. Study profile. CQ, chloroquine; d, day; LCF, Late Clinical Failure; LM, light microscopy; LPF, Late Parasitological Failure; m,
month; PCR, polymerase chain reaction; PQ, primaquine.
https://doi.org/10.1371/journal.pmed.1002784.g001
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Most patients were males (sex ratio M/F = 1.6), and children 3–9 years old represented
almost half (43.08%) of the cohort (Table 1). The M’nong ethnic group (78.46%) in Villages
1–3 was the most represented. All adults were farmers. Most patients were very poor (lowest
income category = 56.54%) and without a bed net at home (70.77%). Beside fever and/or
Table 1. Baseline characteristics of the 260 patients enrolled in the cohort.
Variables n % 95% CI
Village
Village 1 101 38.85 [34.83; 43.02]
Village 2 64 24.62 [21.25; 28.33]
Village 3 39 15.00 [12.84; 17.45]
Village 4 56 21.54 [17.63; 26.04]
Gender
Male 159 61.15 [55.76; 66.82]
Ethnic groups
M0nong 204 78.46 [73.96; 82.37]
Cadong 56 21.54 [17.63; 26.04]
Age groups
3–9 112 43.08 [37.45; 48.89]
10–19 71 27.31 [21.84; 33.55]
20–29 44 16.92 [12.75; 22.11]
30–60 33 12.69 [9.35; 17.00]
Occupation
No (children <6 years old) 70 26.92 [22.02; 32.47]
Farmer 85 32.69 [27.51; 38.34]
Pupil 105 40.38 [34.34; 46.74]
Bed net in house
No 184 70.77 [61.81; 78.37]
At least one 76 29.23 [21.63; 38.19]
Economic status
Lowest income 147 56.54 [47.20; 65.43]
Low 26 10.00 [5.70; 16.96]
Higher 87 33.46 [25.18; 42.90]
Year of recruitment
2009 126 48.46 [41.80; 55.18]
2010 134 51.54 [44.82; 58.20]
Parasite density at day 0 (per μl)
�1,000 56 21.54 [16.90; 27.03]
1,001–5,000 104 40 [33.61; 46.75]
>5,001 100 38.46 [31.86; 45.52]
Asexual parasites/μl (geometric mean) 2,754.07 [2,271.87; 3,338.61]
Infections with gametocytes 224 86.15 [81.37; 89.86]
Clinical symptoms
Fever (axillary temperature�37.5 ˚C) 154 59.23 [53.06; 65.12]
Headache 94 36.15 [30.42; 42.32]
Fatigue 86 33.08 [27.23; 39.50]
Dizziness 28 10.77 [7.51; 15.22]
Enlarged spleen 16 6.15 [3.58; 10.39]
No symptoms 66 25.38 [20.36; 31.16]
The score into tertiles was defined as “high,” “medium,” and “low” economic status.
https://doi.org/10.1371/journal.pmed.1002784.t001
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history of fever, the most frequent symptoms at enrollment were headache and fatigue. The
spleen rate was 6.15% (16/260). The mean parasite density at enrollment was 2,754.1/μl, and
gametocytes were found in most infections (86.15%). By day 3, all patients had cleared infec-
tion and were symptom-free. About half of the patients were recruited in 2009 (48.46%), and
the rest in 2010. The sociodemographic characteristics of patients recruited in 2009 were simi-
lar to those recruited in 2010 except for village, ethnicity, and bed net availability (S1 Table).
Characteristics of vivax recurrences
About two-thirds (76.68%, 171/223) of individuals had at least one PCR-detected recurrence
(median 4 recurrences per patient [IQR 2–6]), 124 (55.61%) at least one patent recurrence
(median = 2/patient; IQR 1–4), and 84 (37.67%) at least one symptomatic recurrence
(median = 1; IQR 1–2) (Table 2). Most patients with PCR-detected (78.95%) and patent recur-
rences (65.32%) had multiple events, while those with symptomatic recurrences (63.10%)
experienced mostly one event. Among the 4,604 visits during the study period, 71 (1.54%)
were unscheduled because of symptomatic vivax recurrences.
Among the 748 PCR-detected P. vivax recurrences, 45% (337/748) were patent, and among
these, 41% (139/337) were symptomatic. The incidence rate was 1.98 per person-years (95% CI
[1.84; 2.12]) for PCR-detected, 0.89 per person-years (95% CI [0.80; 0.99]) for patent, and 0.37
per person-years (95% CI [0.31; 0.43]) for symptomatic recurrences (Table 3). Additionally, a
total of 285 P. falciparum infections were detected by PCR (median: 2 episodes/person [IQR
1–3]; maximum 8/person) of which 240 (84.21%) were patent (median: 1 episode/person [IQR
1–3]; maximum 8), including 149 (/240 = 62.08%) symptomatic infections (median = 1/person
[IQR 1–2]; maximum 6).
Probability of remaining free of vivax recurrence
The Kaplan–Meier probability of remaining free of recurrences by month 24 was 20.40% (95%
CI [14.42; 27.13]) by PCR, 42.52% (95% CI [35.41; 49.44]) by LM, and 60.69% (95% CI [53.51;
67.11]) for symptomatic recurrences (Fig 2A). For P. falciparum recurrences, such probability
Table 2. Characteristic of P. vivax recurrences (all PCR-detected, patent, and symptomatic) detected between
May 2009 and December 2011.
P. vivax recurrences All PCR-
detected
Patent Symptomatic
n % n % n %
Patients free of recurrence 52 23.32 99 44.39 139 62.33
Patients with recurrence: 171 76.68 124 55.61 84 37.67
1 recurrence only 36 21.05 43 34.68 53 63.10
2 recurrences 22 12.87 25 20.16 19 22.62
3 recurrences 20 11.70 18 14.52 6 7.14
4+ recurrences 93 54.38 38 30.64 6 7.14
Number of recurrences/individual (Median [IQR]; max) 4 [2–6]; 13 2 [1–4]; 10 1 [1–2]; 7
Median time from enrollment to first recurrence (days), [IQR] 118 [59–208] 141 [86–237] 181 [97–316]
Time intervals from enrollment to first recurrence:
By day 28 5 2.93 0 0.00 0 0.00
29–180 days 113 66.08 80 64.52 42 50.00
>180 days 53 30.99 44 35.48 42 50.00
Abbreviations: IQR, Interquartile Range; PCR, polymerase chain reaction.
https://doi.org/10.1371/journal.pmed.1002784.t002
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Table 3. Univariable risk factor analysis for first recurrence using Cox PH model and for all recurrences using Cox CGT model (n = 223).
Risk factor Univariate of first recurrence Univariate of all recurrences
n/per year IR HR P-value 95% CI n/per year IR HR P-value 95% CI
All PCR-detected recurrences Overall 171/148.64 1.15 [0.99; 1.34] 748/378.38 1.98 [1.84; 2.12]
Village
Village 1 68/76.40 0.89 1 288/161.07 1.79 1
Village 2 40/34.48 1.16 1.18 0.479 [0.74; 1.87] 144/82.54 1.74 0.97 0.811 [0.79; 1.20]
Village 3 22/24.33 0.9 0.91 0.705 [0.56; 1.48] 74/53.33 1.39 0.83 0.205 [0.61; 1.11]
Village 4 41/13.43 3.05 3.02 <0.001 [2.09; 4.36] 242/81.43 2.97 1.27 0.007 [1.07; 1.51]
Ethnic group
M’nong 130/135.21 0.96 1 506/296.95 1.70 1
Cadong 41/13.43 3.05 2.92 <0.001 [2.06; 4.14] 242/81.43 2.97 1.32 <0.001 [1.13; 1.53]
Prior P. falciparum infection
before P. vivax recurrence
No 154/147.09 1.05 1 645/369.41 1.75 1
Yes 17/1.55 10.94 6.82 <0.001 [5.13; 9.06] 103/8.96 11.49 4.90 <0.001 [4.19; 5.73]
Year of recruitment
2009 99/63.39 1.56 1 526/212.85 2.47 1
2010 72/85.25 0.84 0.57 0.001 [0.42; 0.79] 222/165.53 1.34 0.69 <0.001 [0.57; 0.82]
Bed net in house
No 130/95.02 1.37 1 579/272.22 2.13 1
At least one 41/53.62 0.76 0.59 0.011 [0.39; 0.88] 169/106.16 1.59 0.86 0.119 [0.72; 1.04]
Prior ACT/CQ treatment before P. vivax recurrence
No 653/368.66 1.77 1
Yes 95/9.72 9.78 5.08 <0.001 [4.32; 5.96]
P. vivax density/μl at day 0
<1,000 37/31.42 1.18 1 204/86.50 2.36 1
1,000–5,000 62/55.71 1.11 0.93 0.721 [0.62; 1.40] 252/138.44 1.82 0.83 0.043 [0.69; 0.99]
>5,000 72/61.52 1.17 0.97 0.887 [0.66; 1.43] 292/153.44 1.90 0.85 0.070 [0.71; 1.01]
Economic status
Very low income 99/83.90 1.18 1 385/216.37 1.78 1
Low 16/15.00 1.07 0.90 0.72 [0.49; 1.64] 66/35.14 1.88 1.01 0.926 [0.80; 1.27]
Higher 56/49.75 1.13 0.95 0.762 [0.66; 1.36] 297/126.87 2.34 1.21 0.015 [1.04; 1.40]
Patent recurrences Overall 124/213.09 0.58 [0.49; 0.69] 337/378.38 0.89 [0.80; 0.99]
Village
Village 1 52/96.47 0.54 1 124/161.07 0.77 1
Village 2 24/54.35 0.44 0.79 0.432 [0.45; 1.41] 53/82.54 0.64 0.82 0.310 [0.56; 1.20]
Village 3 11/37.85 0.29 0.57 0.068 [0.31; 1.04] 31/53.33 0.58 0.84 0.468 [0.53; 1.34]
Village 4 37/24.42 1.52 2.53 <0.001 [1.68; 3.81] 129/81.43 1.58 1.59 <0.001 [1.23; 2.07]
Ethnic group
M’nong 87/188.67 0.46 1 208/296.95 0.70 1
Cadong 37/24.42 1.52 2.95 <0.001 [2.00; 4.35] 129/81.43 1.58 1.72 <0.001 [1.36; 2.18]
Prior P. falciparum infection before P. vivax
recurrence
No 107/210.42 0.51 1 280/369.41 0.76 1
Yes 17/2.67 6.38 7.97 <0.001 [5.57; 11.40] 57/8.96 6.36 5.16 <0.001 [3.93; 6.77]
Year of recruitment
2009 82/97.36 0.84 1 244/212.85 1.15 1
2010 42/115.73 0.36 0.43 <0.001 [0.28; 0.65] 93/165.53 0.56 0.59 0.003 [0.42; 0.83]
Bed net in house
No 96/142.67 0.67 1 271/272.22 1.00 1
At least one 28/70.42 0.40 0.61 0.032 [0.39; 0.96] 66/106.16 0.62 0.72 0.038 [0.53; 0.98]
Prior ACT/CQ treatment before P. vivax recurrence
No 290/368.66 0.79 1
Yes 47/9.72 4.84 6.39 <0.001 [4.62; 8.83]
(Continued)
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was 55.61% (95% CI [48.79; 61.90]) by PCR. The median time of remaining free of PCR-
detected recurrence was 174 days—i.e., half of the cohort had experienced a first recurrence
by the sixth month of follow-up, while this was more than double (356 days) for patent recur-
rences. Most of the first events for the three types of recurrences occurred during the first year,
with little changes in the cumulative risk afterwards.
The median time to first recurrence was 118 days (IQR 59–208) by PCR, 141 days (IQR 86–
237) by LM, and 181 days (IQR 97–316) for symptomatic recurrence. Moreover, the median
time to first recurrence tended to be shorter (88 days [IQR 58–1,784]) among patients with
multiple PCR recurrences compared to those with a single PCR recurrence (163 days [IQR
58–291]; Wilcoxon rank sum P< 0.001 [S1 Data]). Time between PCR-detected recurrences
tended to decrease with increasing number of events (Fig 2B); median times between first and
second recurrence (median = 78 days; IQR 43–120) and between second and third recurrence
Table 3. (Continued)
Risk factor Univariate of first recurrence Univariate of all recurrences
n/per year IR HR P-value 95% CI n/per year IR HR P-value 95% CI
Symptomatic recurrences Overall 84/227.14 0.31 [0.25; 0.28] 139/378.38 0.37 [0.31; 0.43]
Village
Village 1 37/118.33 0.31 1 51/161.07 0.32 1
Village 2 11/69.79 0.16 0.48 0.036 [0.24; 0.95] 14/82.54 0.17 0.53 0.039 [0.29; 0.97]
Village 3 10/40.72 0.25 0.78 0.475 [0.40; 1.54] 17/53.33 0.32 1.02 0.946 [0.55; 1.88]
Village 4 26/43.30 0.61 2.02 0.022 [1.11; 3.69] 57/81.43 0.70 2.09 <0.001 [1.38; 3.15]
Ethnic group
M’nong 58/228.84 0.25 1 82/296.95 0.28 1
Cadong 26/43.30 0.60 2.53 0.001 [1.45; 4.41] 57/81.43 0.70 2.36 <0.001 [1.62; 3.45]
Prior P. falciparum infection before P. vivax
recurrence
No 70/268.07 0.26 1 114/369.41 0.31 1
Yes 14/4.07 3.44 9.68 <0.001 [5.67; 16.53] 25/8.96 2.79 5.89 <0.001 [3.73; 9.30]
Year of recruitment
2009 62/132.00 0.47 1 104/212.85 0.49 1
2010 22/140.14 0.16 0.30 <0.001 [0.18; 0.49] 35/165.53 0.21 0.42 0.001 [0.25; 0.71]
Bed net in house
No 63/191.87 0.33 1 113/272.22 0.42 1
At least one 21/80.28 0.26 0.78 0.331 [0.47; 1.30] 26/106.16 0.24 0.63 0.017 [0.44; 0.92]
Prior ACT/CQ treatment before P. vivax recurrence
No 115/368.66 0.31 1
Yes 24/9.72 2.47 5.96 <0.001 [3.87; 9.18]
P. vivax density/μl at day 0
<1,000 18/60.06 0.30 1 40/86.50 0.46 1
1,000–5,000 28/105.31 0.27 0.83 0.525 [0.47; 1.48] 35/138.44 0.25 0.59 0.023 [0.38; 0.93]
>5,000 38/106.77 0.36 1.09 0.762 [0.63; 1.87] 64/153.44 0.42 0.88 0.551 [0.57; 1.35]
Years of education
0 (children) 34/89.10 0.38 1 64/134.14 0.48 1
1–5 26/117.94 0.22 0.58 0.024 [0.37; 0.93] 38/151.47 0.25 0.58 0.020 [0.37; 0.92]
6+ 24/65.11 0.37 0.96 0.845 [0.62; 1.49] 37/92.78 0.40 0.86 0.468 [0.57; 1.29]
n/per year: number of cases per person-years. The following variables were systematically analyzed in both first- and all-recurrences models: village, sex, ethnic groups,
age, age groups, occupation, years of education, bed net in house, economic levels, year of entry, season of entry, parasites density at day 0, prior P. falciparum infection
before P. vivax recurrence, and prior ACT/CQ treatment before P. vivax recurrence. Abbreviations: ACT, artemisinin-based combination therapy; CGT, Conditional
Gap Time; CQ, chloroquine; HR, Hazard Ratio; IR, Incidence Rate; PH, Proportional Hazard.
https://doi.org/10.1371/journal.pmed.1002784.t003
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(median = 60 days; IQR 40–120) were significantly shorter than that to first recurrence
(patients with at least 2 recurrences: median = 88 days, IQR 58–174, P = 0.024; patients with at
least 3 recurrences: median = 88 days, IQR 58–148, P = 0.002). From the fourth to the ninth
recurrence, the median time intervals remained stable at around 60 days, and from the 10th to
the 13th recurrence, at 30 days. A similar pattern was observed with patent recurrences, the
median time intervals stabilizing around 76 days from the third recurrence onwards (S1 Data).
Fig 3 shows a heatmap of all patients’ recurrences by month of follow-up ordered by the
timing of the first recurrence. SM recurrences were frequent in almost all patients and per-
sisted for 2–3 months (up to 7 months) before either clearing spontaneously or becoming
Fig 2. A) Overall Kaplan–Meier probability of remaining free of P. vivax recurrences (either all PCR-identified,
patent, or symptomatic recurrences) and remaining free of P. falciparum infection (by PCR) by month 24 of
follow-up (n = 223); B) time intervals between consecutive P. vivax recurrences identified by PCR (n = 223
patients). Wilcoxon sign rank P-values were computed. �Second time interval was compared to first among patients
with at least two recurrences; ��third time interval was compared to first among patients with at least three
recurrences; ���fourth interval compared to first among patients with at least four recurrences. LM, light microscopy;
PCR, polymerase chain reaction; S, survival probability.
https://doi.org/10.1371/journal.pmed.1002784.g002
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patent or symptomatic. The frequency of symptomatic and patent recurrences decreased with
increasing follow-up time, with a large majority of SM recurrences detected between month 18
and 24 of follow-up.
Risk factors for P. vivax recurrences
Potential risk factors for a first vivax recurrence identified by the univariable analysis, regard-
less of the detection method, were village, ethnicity, bed nets, year of recruitment, and having
a prior (1–2 months) PCR-detected P. falciparum infection (Table 3). This applied also to all P.
vivax recurrences, with the additional strong effect of a prior (1–2 months) antimalarial treat-
ment (ACT or CQ). Since village and ethnicity were highly correlated and only Village 4 (i.e.,
Cadong ethnicity) had a significant effect, only ethnicity was kept in the final model.
In the final Cox PH regression model, only ethnicity, prior P. falciparum infection, and
year of recruitment remained significantly associated with the risk of first PCR-detected
recurrence (Table 4). In addition, for the Cox PH assumption to be verified, the analysis had
to be stratified by year of recruitment. The main risk factor identified for both first and all
vivax recurrences was a prior P. falciparum infection, which increased by 5- to 7-fold the haz-
ard of vivax recurrence. However, this effect was not homogenously distributed among all
patients because there were significant interactions with ethnicity/Village 4 (final model for
Fig 3. Heatmap of P. vivax recurrences by month of follow-up among the 171 cohort patients with at least one recurrence. ID, identifier; PCR,
polymerase chain reaction.
https://doi.org/10.1371/journal.pmed.1002784.g003
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Table 4. Multivariable-adjusted risk factor analysis using Cox PH model for first recurrence and Cox CGT for all recurrences.
First recurrence 2009 Adjusted 2010 Adjusted
HR P-value 95% CI HR P-value 95% CI
All PCR-detected recurrences Effect of ethnicity according to prior P. falciparum infection before P. vivax recurrence: Effect of ethnicity = nonsignificant
No P. falciparum infection 2.21 0.002 [1.33; 3.67] No
P. falciparum infection 0.07 0.059 [0.003; 1.11]
Effect of prior P. falciparum infection before P. vivax recurrence according to ethnic
groups:
Effect of prior P. falciparum before P. vivax
M’nong 99.19 0.001 [6.16; 1,597.55] 1
Cadong 2.98 0.002 [1.48; 5.99] 5.33 0.012 [1.45; 19.62]
Patent Prior P. falciparum infection before P. vivax recurrence
No 1 1
Yes 6.51 <0.001 [3.66; 11.56] 5.92 0.018 [1.36; 25.75]
Symptomatic Prior P. falciparum infection before P. vivax recurrence
No 1
Yes 7.83 <0.001 [4.25; 14.44]
All recurrences 2009 2010
All PCR-detected recurrences Effect of malaria treatment according to prior P. falciparum infection before P. vivax
recurrence:
No P. falciparum infection 6.35 <0.001 [4.32; 9.33] 8.94 <0.001 [5.07; 15.77]
P. falciparum infection 0.72 0.118 [0.47; 1.09] 1.53 0.482 [0.47; 5.02]
Effect of prior P. falciparum infection before P. vivax recurrence according to malaria
treatment:
No malaria treatment 5.89 <0.001 [4.34; 7.98] 5.06 <0.001 [2.57; 9.96]
Malaria treatment 0.66 0.09 [0.41; 1.07] 0.87 0.800 [0.29; 2.63]
Patent Effect of malaria treatment according to prior P. falciparum infection before P. vivax
recurrence:
No P. falciparum infection 21.40 <0.001 [10.61; 43.18]
P. falciparum infection 0.77 0.365 [0.44; 1.35]
Effect of prior P. falciparum infection before P. vivax recurrence according to malaria
treatment:
No malaria treatment 6.34 <0.001 [4.21; 9.54]
Malaria treatment 0.23 <0.001 [0.10; 0.50]
Prior P. falciparum infection before P. vivax recurrence
No 1
Yes 1.80 0.07 [0.96; 3.37]
Prior ACT/CQ treatment before P. vivax recurrence
No 1
Yes 13.83 <0.001 [3.85; 49.72]
Symptomatic Effect of malaria treatment according to prior P. falciparum infection before P. vivax
recurrence:
No P. falciparum infection 6.22 <0.001 [2.80; 13.82]
P. falciparum infection 1.07 0.88 [0.45; 2.54]
Effect of prior P. falciparum infection before P. vivax recurrence according to malaria
treatment:
No malaria treatment 5.65 <0.001 [2.81; 11.35]
Malaria treatment 0.97 0.95 [0.38; 2.46]
Prior ACT/CQ treatment before P. vivax recurrence
No 1
Yes 6.05 0.001 [2.17; 16.86]
Among patients recruited in 2009, a significant interaction term (HR = 0.03; P = 0.016) for the hazard of first PCR-detected recurrence was found between ethnicity and
prior P. falciparum infection. Similarly, significant interaction terms were found for the hazard of all PCR-detected recurrences (HR = 0.11, P< 0.001); patent
recurrences (HR = 0.035, P < 0.001) and symptomatic recurrences (HR = 0.17, P = 0.03). For patients recruited in 2010, a significant interaction term (HR = 0.17;
P = 0.008) for the hazard of all PCR-detected recurrences was found between prior P. falciparum infection and prior antimalaria treatment. Abbreviations: ACT,
artemisinin-based combination therapy; CGT, Conditional Gap Time; CQ, chloroquine; HR, Hazard Ratio; PCR, polymerase chain reaction; PH, Proportional Hazard.
https://doi.org/10.1371/journal.pmed.1002784.t004
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first recurrence) and prior antimalaria treatment (final model for all recurrences). Indeed,
among patients recruited in 2009, the hazard of having first PCR-detected recurrence after a
prior falciparum infection was 3-fold higher among Cadong (HR = 2.98; 95% CI [1.48; 5.99];
P = 0.002) and at least 6-fold higher among M’nong (HR = 99.19; 95% CI [6.16; 1,597.55];
P = 0.001) patients. Conversely, the hazard of first PCR recurrence was 2-fold higher in
Cadong than in M’nong patients (HR = 2.21; 95% CI [1.33; 3.67]; P = 0.002), but only in
those without a prior falciparum infection. In 2010, few Cadong patients were recruited, and
thus the effect of ethnicity/Village 4 was no longer significant; thus, only prior falciparum
infection remained significantly associated with the hazard of both first PCR-detected and
patent recurrence. None of the patients recruited in 2010 had a falciparum infection before
their first symptomatic recurrence.
Similarly, the final Cox CGT models for all recurrences among patients recruited in 2009
and 2010 showed that the hazard of PCR-detected vivax recurrences after a prior falciparum
infection (versus no P. falciparum) was 5- to 6-fold higher, but only in patients without previ-
ous antimalaria treatment (i.e., SM falciparum infections). Conversely, the effect of prior
antimalarial treatment (versus no treatment) was very strong in both recruitment years
(respectively, HR = 6.35 and HR = 8.94; P< 0.001), but only in individuals without a prior fal-
ciparum infection, i.e., patent recurrences treated with CQ. For patent and symptomatic recur-
rences, a similar pattern was observed for patients recruited in 2009.
The hazard of patent recurrences was significantly higher (HR = 6.34; P< 0.001) in patients
with a prior untreated falciparum infection, while the opposite effect was observed in patients
who were treated (HR = 0.23; P< 0.001). For patients recruited in 2010, only prior antimalar-
ial treatment remained significantly associated with the risk of patent (HR = 13.83; P< 0.001)
and symptomatic recurrences (HR = 6.05; P< 0.001). Fig 4A shows the study timeline with
corresponding climatic data; Fig 4B shows the evolution of the cohort size by calendar month
together with the proportion of study patients with vivax recurrences (PCR-detected, patent,
and symptomatic) as well as the contemporary monthly incidence risk of P. falciparum infec-
tions (Fig 4B) as detected by PCD and ACD (LM) in the four study villages. The first mass
distribution of long-lasting insecticidal nets (LLINs) in the study area occurred in September
2010 and was followed by a steady decrease in both the risk of P. falciparum infections in the
study area and of P. vivax recurrences among cohort patients (Fig 4B). The monthly incidence
risk of P. falciparum decreased to almost zero from February 2011 until the end of follow-up;
similarly, the risk of all PCR-detected and patent vivax recurrences steadily decreased to 7%
and 1%, respectively, by December 2011.
Discussion
Post-treatment vivax recurrences were extremely frequent, especially SM infections, which
tended to occur earlier than patent or symptomatic infections. Prior falciparum infection was
the main risk factor for all types of vivax recurrence (first and all recurrences; PCR-detected,
patent, and symptomatic recurrences) together with prior CQ treatment for the risk of
repeated recurrences. The drop-out rate was low given the length of follow-up, and most with-
drawals occurred during the 10-day PQ treatment.
Although collected about ten years ago, our results remain relevant for Vietnam where
the current challenges for malaria elimination include i) the increasing relative frequency
of P. vivax malaria, from 25% of all cases in 2009 to 51% in 2015 [9]; and ii) the spread of arte-
misinin resistance [29]. In addition, the downward trend of annual malaria incidence has
changed as the total number of confirmed cases started to increase in 2017, with a 16%
increase observed in 2018 (4,813 cases) compared to 2016 (4,161 cases) [30,31], mostly due to
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P. falciparum; cases were observed mainly in a few provinces in Central Vietnam where arte-
misinin resistance has been reported [32].
Despite PQ directly observed treatment, 8% of patients (most withdrawals) withdrew their
consent during the 10-day treatment, emphasizing the difficulty of achieving good compliance
for PQ radical treatment [18,33]. In our cohort, PQ was only used at the time of recruitment
and at the end of each patient’s follow-up. This is probably similar to the true situation in remote
areas in Vietnam, including our study area, where the health staff is reluctant to administer PQ
in the absence of diagnostic tests for G6PD deficiency [16]. Tafenoquine, a new 8-aminoquino-
line with prolonged half-life recently approved by the US Food and Drug Administration [3],
will not change this situation because it will be administered only after performing a quantitative
G6PD rapid test [34], although the single-dose scheme will improve compliance.
Incidence of PCR-detected vivax recurrence was>2-fold higher than that of patent recur-
rence and 5-fold higher than symptomatic recurrence, suggesting a much larger infection reser-
voir than estimated by standard diagnostic tools (LM/RDT) and current surveillance strategies
Fig 4. A) Monthly climatic data in the study area; B) monthly evolution of the cohort size with proportion of
patients identified with P. vivax recurrence (all PCR-identified, all patent, and all symptomatic) and the monthly
incidence risk of P. falciparum infections detected by ACD and PCD (LM) in study population. ACD, active case
detection; LM, light microscopy; PCD, passive case detection.
https://doi.org/10.1371/journal.pmed.1002784.g004
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(PCD and Re-ACD). Although some of the PCR-detected infections at different time points
may be the same infection, possibly overestimating the incidence of recurrent infections, their
persistence for long periods of time (up to 7 months) contributes to maintaining transmission.
Our results corroborate the findings of a recent cohort study in Central Vietnam in which the
median duration of SM P. vivax infections was 6 months (IQR 3–9), with parasite densities
oscillating from ultralow to high density between monthly samples [35]. Since SM vivax infec-
tions with gametocytes can successfully infect mosquitoes [36,37], all PCR-detected vivax infec-
tions should be considered as potentially infectious, regardless of parasite density or presence
of gametocytes at time of sampling, and effectively treated in order to interrupt transmission.
Although the annual malaria incidence reported by PCD has further decreased since 2011,
with no falciparum malaria cases since 2016 (S2 Table), the current proportion of SM vivax
infections may be similar to that observed in our study. Indeed, during the last 6 months of our
cohort study, in 2011, when malaria transmission had decreased substantially, PCR-detected
vivax recurrences were significantly more frequent than patent or symptomatic infections. In a
recent systematic review [38], SM vivax infections probably represent about 67% of all PCR-
detected vivax infections and are negatively correlated, as for P. falciparum [22], with the preva-
lence of patent vivax infections. This suggests that, despite the observed reduction of patent vivax
and falciparum cases since 2011, the proportion of SM vivax infections may not have changed;
this should be further confirmed by large-scale prevalence surveys using both PCR and LM.
P. falciparum infections were identified as the main risk factor for first and repeated vivax
recurrences. The triggering effect of symptomatic P. falciparum infections on P. vivax relapses
has been known since the 1920s [39] and has been reported in other cohort studies in Asia [40–
42]. Interestingly reported and for the first time, to our knowledge, in our study, falciparum
infections were a strong risk factor for repeated vivax recurrences, but only in patients untreated
(with either CQ or DHA-PQ) at the previous visit, while if treated, falciparum infection tended
to be protective. This suggests that chronic SM falciparum infections can trigger vivax recur-
rences, while antimalarial treatment, by clearing falciparum infections, prevents vivax recur-
rence. Though it remains unclear whether P. falciparum triggered vivax relapses or suppressed
vivax parasites during coinfections, our results suggest that chronic SM falciparum infections
could trigger vivax recurrences, hence contributing to the human reservoir of P. vivax infec-
tions. This, together with previous evidence [40–42], calls for new and integrated treatment
strategies tackling both species simultaneously, e.g., treating all malaria infections, regardless of
the species, with one ACT and antirelapse drug (PQ or tafenoquine) [43]. The increased risk of
vivax recurrence related to previous antimalarial treatment in patients without prior falciparum
infection suggests CQ vivax resistance as confirmed earlier in the same cohort [44].
It is not possible to distinguish between new infections and relapses within our cohort. Nev-
ertheless, assuming a similar incidence of P. falciparum and P. vivax new infections, the differ-
ence between the PCR-detected vivax and falciparum infections’ Kaplan–Meier curves should
provide the relative contribution of vivax relapses, i.e., around 50%. This compares well with
the results of a trial comparing artesunate alone or combined with PQ in Papua New Guinea,
where P. falciparum and P. vivax sporozoite rates in the local vector population were compara-
ble [45].
The total PQ dose administered (5.0 mg/kg) was lower than that recommended by WHO,
i.e., 7.0 mg/kg [46]. A recent systematic review reported that a total PQ dose�5.0 mg/kg had
the lowest risk of recurrence (median = 0%; range 0%–15%) than the very low (�2.5 mg/kg)
and low total dose (>2.5 and<5.0 mg/kg) [5]. This confirmed a previous review concluding
that 0.5 mg/kg/day for 14 days was the recommended dose in nonpregnant subjects without
G6PD deficiency [47]. Although it is impossible to know whether a 2.0 mg/kg difference in PQ
dosage would have affected the risk of first recurrence, the synergistic effect of combining CQ
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with PQ could have been hampered by P. vivax CQ resistance, which was observed in our
cohort [44]. This is also suggested by the strong deleterious effect of prior CQ treatment on
all types of vivax recurrence in 2009 and for the PCR-detected recurrences in 2010. CQ resis-
tance in P. vivax should be carefully monitored in Vietnam, and treatment for vivax patients
changed to an ACT in case of substantial resistance [48,49].
A major limitation of this study is the absence of a comparator arm in which all vivax recur-
rences would have been systematically treated with PQ; this would have enabled estimating the
relative contribution of vivax relapses to recurrent infections [45]. However, such a design was
not chosen given the low incidence rates of symptomatic vivax infections (main inclusion cri-
teria), which would have required an even longer recruitment period that could not be sup-
ported by the available budget.
As mentioned earlier, the age of the data represents another limitation because malaria
continued to decrease steadily after the end of the study, with no falciparum cases reported in
2016 and 2017 (S2 Table). However, as mentioned earlier, P. falciparum is on the rise in Cen-
tral Vietnam, and the province of Quang Nam also reported an increase in P. falciparum cases
in 2018 (+4% compared to 2017). Therefore, even though the data presented in this paper are
not directly comparable to the current situation in the study area, the challenges they under-
line, i.e., the elimination of P. vivax and of artemisinin-resistant P. falciparum in Central Viet-
nam, remain more than ever relevant.
Because hemoglobin (Hb) levels were not monitored during the follow-up, it was not possi-
ble to determine the risk and severity of anemia related to vivax recurrences, especially for the
prolonged SM vivax infections, which was another major limitation. Finally, in our statistical
analysis, the different sampling schemes underlying scheduled and unscheduled visits were
not considered. Nevertheless, the related bias is probably minor because of the intense
monthly sampling and the moderate number of unscheduled visits (4.533 scheduled visits ver-
sus 71 unscheduled visits). Further research should focus on developing appropriate method-
ology taking into account the outcome-dependent sampling underlying unscheduled events,
especially in case of larger time gaps between scheduled visits [50].
In conclusion, this large cohort study identified a high burden of post-treatment vivax
infections, mainly asymptomatic and SM, despite a high-dose PQ regimen (total 5 mg/kg)
administered under direct observation. The main risk factors for vivax recurrence were prior
P. falciparum infections—particularly the SM ones, which were untreated because they were
not detected immediately after sampling and persisted for several months—and prior CQ
monotherapy, indicating vivax drug resistance. When considering Vietnam reverted to the
standard PQ dose of 0.25 mg/kg/day for 14 days, which is often not prescribed or supervised,
the current vivax parasite reservoir, despite the decreasing number of reported cases, may be
larger than estimated by standard diagnostic tools. This calls for improved treatment (e.g., sin-
gle-dose tafenoquine with G6PD testing) and surveillance strategies (including the detection
of SM infections) tackling simultaneously P. falciparum and P. vivax infections if malaria elim-
ination is to be achieved by 2030 as endorsed by the Vietnamese government.
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